J&JJanssens Cilag to CoDevelop argenxs Cusatuzumab in $1.8B Collaboration

J&J/Janssen’s Cilag to Co-Develop argenx’s Cusatuzumab in $1.8B+ Collaboration

Cilag International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, will partner with argenx to develop its cancer-fighting antibody cusatuzumab (ARGX-110), through a collaboration that could generate more than $1.8 billion for argenx, the companies said today. Cusatuzumab is now in development in a Phase I/II combination study with Vidaza® (azacytidine or […]

More From BioPortfolio on "J&J/Janssen’s Cilag to Co-Develop argenx’s Cusatuzumab in $1.8B+ Collaboration"